TRZ GLP-2

GLP-T is a synthetic unimolecular dual incretin receptor agonist peptide designed to simultaneously engage both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIP and GLP-1 are two distinct incretin hormones released from the gastrointestinal tract following nutrient consumption, and while they share the downstream goal of potentiating glucose-stimulated insulin secretion, they act through different receptor distributions across tissues and produce complementary metabolic effects. GLP-1R agonism primarily drives insulin secretion, glucagon suppression, and appetite reduction, while GIPR agonism acts on adipose tissue to enhance insulin sensitivity, improve lipid storage capacity, and reduce ectopic fat accumulation. By combining both activities in a single peptide molecule, GLP-T is used in research to study the synergistic effects of dual incretin receptor co-activation on glycemic control, body weight regulation, hepatic lipid metabolism, and beta-cell function. This product is supplied in two dose quantities (15mg and 30mg) to support dose-response experimental design. For research use only. Not for human consumption.

Chemical Structure and Identification

• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight: Approximately 4813.5 g/mol
• CAS Number: 2023788-19-2

Research Applications

• Dual Incretin Receptor Signaling: Investigation of simultaneous GIPR and GLP-1R co-activation and its synergistic effects on insulin secretion, beta-cell cAMP production, glucagon suppression, and postprandial glucose regulation in islet cell models [1]
• Adipose Tissue and Lipid Metabolism Research: Study of GIPR-mediated effects on white adipose tissue function, dietary lipid storage, and lipid spillover reduction in the context of dual agonism and diet-induced obesity preclinical models [2]
• Hepatic Steatosis and Liver Disease Research: Examination of dual GIP/GLP-1 receptor agonist effects on hepatic lipid accumulation, steatohepatitis markers, and fibrosis-related gene expression in metabolic liver disease models [3]
• Beta-Cell Function and Preservation: Analysis of combined GIPR and GLP-1R co-stimulation on beta-cell proliferation, apoptosis resistance, and long-term functional mass in type 2 diabetes preclinical models [4]

Reference Citations

1. PMC8011784 | https://pmc.ncbi.nlm.nih.gov/articles/PMC8011784/
2. Coskun T et al. (2018) – Mol Metab | https://pubmed.ncbi.nlm.nih.gov/30473097/
3. PMC12323726 | https://pmc.ncbi.nlm.nih.gov/articles/PMC12323726/
4. PMC8348147 | https://pmc.ncbi.nlm.nih.gov/articles/PMC8348147/

Important Regulatory Notice

These products are for research use only and are not intended for human consumption, therapeutic use, or diagnostic purposes. All compounds described herein have not been approved by the FDA for human use. These products are strictly intended for in vitro laboratory research and analytical purposes when conducted by qualified research professionals in licensed facilities. Users are responsible for ensuring compliance with all applicable laws regarding purchase and use of these materials.